- Flagship Pioneering unveils Etiome with a $50 million initial commitment.
- The Temporal Biodynamics™ platform is the first AI-powered, end-to-end solution for preemptive healthcare.
- Etiome will initially target metabolic, neurodegenerative, pre-cancerous, and autoimmune diseases.
Flagship Pioneering has launched Etiome, a cutting-edge company devoted to reshaping disease detection and prevention. With an initial commitment of $50 million from Flagship Pioneering, Etiome introduces its Temporal Biodynamics™ platform, an AI-driven technology designed to transform healthcare by preempting life-threatening diseases before they progress.
Etiome's platform is the first of its kind to provide an end-to-end solution that not only predicts how diseases progress over time but also targets interventions at critical stages. By utilizing multimodal population-level data combined with single-cell omics and artificial intelligence, the platform identifies Biostage Markers—stage-specific biomarkers that chart a patient's disease trajectory. This approach enables the development of Biostaged Medicines designed to halt or reverse disease progression.
The company is initially focusing on addressing significant unmet needs in metabolic, neurodegenerative, pre-cancerous, and autoimmune diseases. These conditions affect broad patient demographics and present substantial healthcare challenges.
Founded from Flagship Pioneering's Preemptive Health and Medicine Initiative, Etiome aims to reduce morbidity, lower healthcare costs, and extend healthy lifespans by intervening in diseases before they become critical. Etiome boasts a leadership team with expertise in biology, omics, and artificial intelligence, including Avak Kahvejian, Ph.D., as Founding CEO, supported by a board with affiliations to Gates Ventures and Microsoft's Health division.
